Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24975784 | 1.00 | LTA4H (0.46) | LTA4HSIGMAR1CYP3A4CXCR4KDM1A | |
| SCHEMBL4851071 | 0.84 | LTA4H (0.51) | LTA4HSIGMAR1CYP3A4CXCR4 | |
| SCHEMBL11097602 | 0.77 | LTA4H (0.41) | LTA4HSIGMAR1CYP3A4CXCR4 | |
| SCHEMBL11094109 | 0.76 | LTA4H (0.58) | LTA4HCYP3A4CXCR4 | |
| SCHEMBL11266772 | 0.74 | LTA4H (0.48) | LTA4HSIGMAR1CYP3A4CXCR4 | |
| SCHEMBL24135073 | 0.72 | SIGMAR1 (0.50) | SIGMAR1CYP3A4 | |
| SCHEMBL24977220 | 0.71 | L3MBTL1 (0.53) | LTA4HCYP3A4CXCR4KDM1A | |
| SCHEMBL24975769 | 0.71 | L3MBTL1 (0.53) | LTA4HCYP3A4CXCR4KDM1A | |
| SCHEMBL24976021 | 0.71 | L3MBTL1 (0.53) | LTA4HCYP3A4CXCR4KDM1A | |
| SCHEMBL4031887 | 0.70 | CYP3A4 (0.54) | LTA4HSIGMAR1CYP3A4CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | AMGEN INC. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | CYP3A7, CYP51A1, NT5C3B | LTA4H 3016/4885SIGMAR1 1641/4885CYP3A4 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.